Regulation of membrane permeability by a two-component regulatory system in Pseudomonas aeruginosa

被引:40
作者
Wang, YP [1 ]
Ha, U [1 ]
Zeng, L [1 ]
Jin, SG [1 ]
机构
[1] Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA
关键词
D O I
10.1128/AAC.47.1.95-101.2003
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Membrane impermeability is the major contributing factor to multidrug resistance in clinical isolates of Pseudomonas aeruginosa. By using laboratory strain PAK, a spontaneous P. aeruginosa mutant (mutant PAK1-3) whose membrane had reduced permeability and which displayed increased levels of resistance to various antibiotics, especially aminoglycosides, was isolated. By complementation of the mutant with a genomic clone library derived from wild-type strain PAK, a novel two-component regulatory system (PprA and PprB) was identified and was found to be able to increase the permeability of the bacterial membrane and render PAK1-3 sensitive to antibiotics. Furthermore, specific phosphorylation of the response regulator (PprB) by histidine kinase (PprA) was observed in vitro, demonstrating that they are cognate two-component regulatory genes. Introduction of a plasmid expressing the pprB gene into randomly chosen clinical isolates (n = 17) resulted in increased sensitivity to aminoglycosides in the majority of isolates (n = 13) tested. This is the first demonstration that P. aeruginosa membrane permeability can be regulated, providing an important clue in the understanding of the mechanism of membrane impermeability-mediated multidrug resistance in P. aeruginosa.
引用
收藏
页码:95 / 101
页数:7
相关论文
共 38 条
[1]   Emergence of multidrug-resistant mutants is increased under antibiotic selective pressure in Pseudomonas aeruginosa [J].
Alonso, A ;
Campanario, E ;
Martínez, JL .
MICROBIOLOGY-SGM, 1999, 145 :2857-2862
[2]  
BODEY GP, 1983, REV INFECT DIS, V5, P279
[3]   LIPOPOLYSACCHARIDE CHANGES IN IMPERMEABILITY-TYPE AMINOGLYCOSIDE RESISTANCE IN PSEUDOMONAS-AERUGINOSA [J].
BRYAN, LE ;
OHARA, K ;
WONG, S .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1984, 26 (02) :250-255
[4]  
BRYAN LE, 1988, J ANTIMICROB CHEMOTH, V22, P1
[5]   Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis [J].
Burns, JL ;
Van Dalfsen, JM ;
Shawar, RM ;
Otto, KL ;
Garber, RL ;
Quan, JM ;
Montgomery, AB ;
Albers, GM ;
Ramsey, BW ;
Smith, AL .
JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (05) :1190-1196
[6]   MICROBIOLOGY OF AIRWAY DISEASE IN PATIENTS WITH CYSTIC-FIBROSIS [J].
GILLIGAN, PH .
CLINICAL MICROBIOLOGY REVIEWS, 1991, 4 (01) :35-51
[7]   STUDIES ON TRANSFORMATION OF ESCHERICHIA-COLI WITH PLASMIDS [J].
HANAHAN, D .
JOURNAL OF MOLECULAR BIOLOGY, 1983, 166 (04) :557-580
[8]  
Holder Ian Alan, 1993, P235
[9]  
Karlowsky JA, 1997, PHARMACOTHERAPY, V17, P549
[10]  
LeClerc JE, 2000, SCIENCE, V289, P391